James Willhite was an editor with The Wall Street Journal's money & investing team based in London.

Brianna Abbott is a health reporter covering the treatment and prevention of disease, with a special focus on cancer, in The ...

Clinical academia is on a steep decline globally. In the UK, a 6% reduction in the number of clinical academics since 2012 has been reported, with the number of senior lecturer level researchers ...

The biotech and hospital have expanded their collaboration, with Alcyone now advancing a gene therapy for Batten disease that the hospital was developing.

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $217.00. The ...

Kendall Square has become a hub of biotech innovation and a popular location for up and coming life sciences firms. Now, a ...

Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Friedreich's ataxia is a widespread hereditary ataxia type, affecting a minimum of one in every 50,000 individuals. It is c ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...